Plus Therapeutics, Inc. announced that it will participate in the upcoming 2024 Congress of Neurological Surgeons (CNS) Annual Meeting. The event will take place in Houston, Texas from September 28 to October 2. The company will present data from its Phase 2 trial on treating recurrent glioblastoma (rGBM).
The presentation will focus on the use of Rhenium (186Re) Obisbemeda, an injectable radiotherapy, in fighting central nervous system (CNS) cancers. Dr. John Floyd from UT Health Science San Antonio will be delivering the update on the ReSPECT-GBM trial.
Glioblastoma is a deadly brain cancer that affects around 15,000 U.S. patients each year. The prognosis is poor, with patients surviving an average of less than 24 months after diagnosis. Current treatments have limited benefits and severe side effects. Rhenium (186Re) Obisbemeda aims to deliver precise high-dose radiation to CNS tumors, potentially reducing risks and improving patient outcomes.
The development of this treatment is supported by funding from the National Cancer Institute (NCI) and a grant from the Cancer Prevention & Research Institute of Texas (CPRIT). Plus Therapeutics is also exploring the use of the therapy for leptomeningeal metastases in the ReSPECT-LM clinical trial.
Convection Enhanced Delivery (CED) is the method used to administer Rhenium (186Re) Obisbemeda, involving minimally invasive surgery and direct catheter placement into the brain tumor for targeted drug delivery.
Based in Austin and San Antonio, Texas, Plus Therapeutics is dedicated to developing targeted radiotherapeutics for challenging CNS cancers. The company has formed strategic partnerships for the development, manufacturing, and potential commercialization of its products.
In other news, Plus Therapeutics faces potential delisting from The Nasdaq Stock Market due to an equity shortfall. Despite this, the company plans to appeal the decision.
The company reported Q2 revenue of $1.3 million, falling short of expectations and leading to revised revenue estimates for the year. Plus Therapeutics reported a net loss higher than estimated.
Plus Therapeutics elected new board members, received approval for an amendment to its Stock Incentive Plan, and reported positive results from its ReSPECT-LM trial for rhenium obisbemeda. The company also has a solid financial position and has secured grants for further research. Investors are closely monitoring the company’s financial performance and stock prices.
Read More
Fed projects 0.5% rate cut by year-end